Asthma treatment

http://www.healasthma.com past six monthsthe past twelve months Search Hint Connecting terms with OR broadens your search to give more results …more on search operators – . Canada Newswire (Canada) – Two inhalers are better than one for common lung disease CNW Telbec – A publicly funded cross-Canada clinical trial has revealed that combining the inhalers Spiriva(TM) (tiotropium) and Advair(TM) (fluticasone/salmeterol) results in improved quality of life, improved lung function, and fewer hospitalizations among people with severe Chronic Obstructive Pulmonary Disease (COPD). More than five per cent of Canadians over the age of have been diagnosed with COPD, an incurable disease also referred to as emphysema and chronic bronchitis…. GlaxoSmithKline posts percent increase in quarterly profit Led by booming U.S. sales of its new asthma drug Advair, GlaxoSmithKline PLC posted a percent increase in fourth quarter profits, as it reported its first full-year financial results since the merger of Glaxo Wellcome PLC and SmithKline Beecham Corp. GlaxoSmithKline reported net income Thursday of . billion pounds ( . billion), up from . billion pounds in the fourth quarter of .Sales for the quarter ending Dec. rose percent to . billion pounds ( . … Glaxo posts % quarterly profits New asthma drug boosts GlaxoSmithKline, up % in ‘ , its first full-year results since the merger LONDON – Led by booming U.S. sales of its new asthma drug Advair, GlaxoSmithKline PLC posted a percent increase in fourth quarter profits, as it reported its first full-year financial results since the merger of Glaxo Wellcome PLC and SmithKline Beecham Corp.GlaxoSmithKline reported net income Thursday of . billion, up from . billion in the fourth quarter of . Excluding more than . billion in merger-related costs, GlaxoSmithKline’s quarterly operating profit… Restrict asthma drugs, say experts Government health advisers recommended restrictions Thursday on some long-acting asthma drugs, although not Advair, a top-selling medication.Outside experts advising the Food and Drug Administration said Foradil and Serevent no longer should be used for asthma. But they said the benefits of the more widely used Advair and Symbicort clearly outweigh the risks.Each contains an ingredient that relaxes muscles around stressed airways. But that mask symptoms that can trigger… . FDA divided on asthma medicines An FDA scientist argued yesterday that asthma sufferers should no longer use four popular asthma drugs, including GlaxoSmithKline P.L.C.’s Advair and AstraZeneca P.L.C.’s Symbicort, because they increase the risk of death. But another scientist from the agency called that opinion “extreme” and said it would leave asthma patients with few treatments.The comments came during an agency review of drugs known as long-acting… . Evening Standard, The (London, England) – Evening Standard Brokers split over FDA’s blow for Glaxo THE City has mixed views about prospects for drugs giant Glaxo- SmithKline following criticism by the powerful US Food and Drug Administration (FDA) that higher dosages of its asthma treatment Advair had no advantage for sufferers of chronic obstructive pulmonary disease .Overnight the FDA complained there was not enough evidence to indicate that patients treated with higher dosages of Advair lived any longer than those not treated with the product.Shares of Glaxo reacted to the… . New Zealand Herald (New Zealand) – New Zealand Herald Glaxo hit after FDA warning . . . pm Shares in GlaxoSmithKline, Europe’s largest drug company, fell almost per cent yesterday after the US Food & Drug Administration agency (FDA) announced plans to restrict the use of its best-selling asthma treatment, Advair.The FDA published its proposals – which will aim to prevent doctors from recommending Advair as a first-line of treatment for asthma patients – on Friday evening in the US, after the London market had closed.Analysts said… Safety of three asthma drugs is considered A panel of lung experts was considering Wednesday whether to ban the asthma drugs Advair, Serevent and Floradil because of safety concerns. The Food and Drug Administration says the three drugs, in a small number of patients, have have been associated with severe asthma exacerbations, The New York Times reported Wednesday Advair and Serevent, are made by GlaxoSmithKline, and Floradil, developed by Novartis, is sold in the United States by Schering Plough.The drugs are inhaled to… . EASIER-TO-TAKE ASTHMA DRUG RECOMMENDED An asthma medicine that doctors hope will make it easier for patients to adhere to their therapy took a step toward the market Tuesday as government advisers recommended approval of Advair.Advair is not actually a new drug. It merely combines into one inhaler device two existing asthma treatments – the long-acting inhaled bronchodilator Serevent that helps keep airways open and the inhaled corticosteroid Flovent that fights inflammation.Manufacturer Glaxo Wellcome estimates about … FDA committee recommends easier-to-take asthma drug An asthma medicine that doctors hope will make it easier for patients to adhere to their therapy took a step toward the market Tuesday as government advisers recommended approval of Advair. Advair is not actually a new drug. It merely combines into one inhaler device two existing asthma treatments — the long-acting inhaled bronchodilator Serevent that helps keep airways open and the inhaled corticosteroid Flovent that fights inflammation.Manufacturer Glaxo Wellcome estimates about… –